Skip to content
OpenCapital
Get started

Kymera Therapeutics KYMR Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$225.1M+6.3%
Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's deferred revenue, net of current portion?
Kymera Therapeutics (KYMR) reported deferred revenue, net of current portion of $0 in Q1 2026.
What is the long-term trend for Kymera Therapeutics's deferred revenue, net of current portion?
Over 5 years (2020 to 2025), Kymera Therapeutics's deferred revenue, net of current portion has grown at a -31.9% compound annual growth rate (CAGR), from $77.84M to $11.44M.